Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.
William G. Wierda, John C. Byrd, Jeremy S Abramson, S Bilgrami, Greg Bociek, Danielle M. Brander, Jennifer R. Brown, Asher Chanan‐Khan, Julio C. Chávez, Steven Coutré, Randall S. Davis, Christopher D.�M. Fletcher, Brian T. Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Megan S. Lim, Shuo Ma, Sami N. Malek, Anthony Mato, Claudio A. Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah M. Stephens, Suchitra Sundaram, Nina Wagner, Mary Dwyer, Hema Sundar
Abstract
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in recent years because of the improved understanding of the disease biology and the development of novel targeted therapies. In patients with indications for initiating treatment, the selection of treatment should be based on the disease stage, patient's age and overall fitness (performance status and comorbid conditions), and cytogenetic abnormalities. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.